Estradiol: 4 agencies, 2020–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused estradiol: all 5 decisive outcomes across 2 agencies were positive or positive with restrictions.
Assessment has run over 5.8 years, from 10 Sep 2020 at AWMSG (Wales) to 2026 at PBAC (Australia).
No assessment is on file from SMC (Scotland), PHARMAC (New Zealand), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for estradiol, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 6 of 8 records date from 2023 or later.
4 distinct indication wordings are recorded for estradiol by the agencies that label one in English (AWMSG and PBAC).
4 of these 8 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess estradiol, on 10 Sep 2020; HAS (France) did not open a file until 24 Sep 2025 — a wide spread of 5 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
2 of the 4 agencies here assessed estradiol more than once, PBAC (Australia) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed estradiol.
The full ledger for estradiol reads 5 recommended, 2 withdrawn and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 24 Sep 2025 | Re-assessment at ministerial request (Transparency Committee) | SMR substantial · ASMR IV | source |
| PBAC (Australia) | 2025 | Vasomotor symptoms in post menopausal women | Recommended | source |
| CIPM (Spain) | 11 May 2023 | Indicación terapéutica autorizada: Terapia Hormonal Sustitutiva (THS) para los síntomas de la deficiencia de estrógenos … | excluded from SNS provision · art. 92 b | source |
| CIPM (Spain) | 14 Oct 2020 | Indicación terapéutica: Terapia de sustitución de estrógeno para corregir la deficiencia de estrógeno y síntomas asociad… | excluded from SNS provision | source |
| AWMSG (Wales) | 10 Sep 2020 | Sequential hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women (in women at leas… | outside AWMSG criteria | source |
3 further decisions for estradiol, across 1 agency, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset.
Related molecules
- ethinylestradiol / levonorgestrel — same ATC class G03C — Sex hormones and modulators
- ethinylestradiol / gestodene — same ATC class G03C — Sex hormones and modulators
- estriol — same ATC class G03C — Sex hormones and modulators
- estradiol / norethisterone / relugolix — same ATC class G03C — Sex hormones and modulators
- dydrogesterone — also decided by HAS in 2025Q3
- cefazolin — also decided by HAS in 2025Q3
Coverage: 8 decisions for estradiol from 4 agencies, 2020 to 2026. Data to 7 Sep 2026. ATC class G03C — Sex hormones and modulators. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.